Pursuant to clause 33 of the Listing Obligations and Disclosure requirements (LODR), Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Monday, 22th October, 2018, to consider and approve Un-Audited Financial Results for the quarter and half year ended 30th September, 2018.
The above information is a part of company’s filings submitted to BSE.